ARA 290

This peptide works on the peripheral and central nervous system. It has the ability to help regrow some types of nerves. It is mostly used for neuropathic pain or pain in general. Though, this peptide can do a wide range of different things. ARA 290 works on the innate repair receptor that is activated with injury or inflammation. It can inhibit the pro-inflammatory response of the body. It can work against an overactive immune system to down regulate how the immune system would handle insults that may not actually be foreign bodies trying to attack the body. This could lead to help in autoimmune conditions as well. Some areas of interest for this peptide include increasing insulin sensitivity, nerve pain, heart and cardiovascular disease among a few of the disease processes noted. It can up regulate energy in the cell as well.

Helps with:
-       Shingles
-       Sarcoidosis
-       Insulin sensitivity
-       Diabetic retinopathy
-       Nerve pain
-       Mild traumatic brain injuries
-       Potentially heart and cardiovascular diseases
-       Potentially neurodegenerative disorders (Parkinson’s and Alzheimer’s)
-       Potentially spinal cord injuries
-       Potentially stroke

1.     Brines, M., (2018). Corneal Nerve Fiber Size Adds Utility to the Diagnosis and Assessment of Therapeutic Response in Patients with Small Fiber Neuropathy. Sci Rep, 8, 4734. DOI: 10.1038/s41598-018-23107-w
2.     Dahan, A, et al. (2013). ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. Mol Med, 19(1), 334–345. DOI: 10.2119/molmed.2013.00122
3.     Huang, B., et al. (2018). Non-erythropoietic Erythropoietin-derived Peptide Protects Mice from Systemic Lupus Erythematosus. J Cell Mol Med, 22(7), 3330–3339. DOI: 10.1111/jcmm.13608
4.     Liu, Y., et al. (2014). Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis by Inflammation Suppression and Tissue Protection. PLoS One 9(3), e90942. DOI: 10.1371/journal.pone.0090942
5.     Muller, C., et al. (2015). ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Mol Med, 21(1), 969–978. DOI: 10.2119/molmed.2015.00267
6.     Swartjes, M., et al. (2014). ARA 290, A Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response.Mol Pain, 10, 13. DOI: 10.1186/1744-8069-10-13
7.     van Rijt, W. G., et al. (2013). Renoprotective Capacities of Non-erythropoietic EPO Derivative, ARA290, Following Renal Ischemia/Reperfusion Injury. J Transl Med, 11, 286. DOI: 10.1186/1479-5876-11-286
8.     van Rijt, W. G., et al. (2013). ARA290, a Non-erythropoietic EPO Derivative, Attenuates Renal Ischemia/Reperfusion Injury. J Transl Med, 11, 9. DOI: 10.1186/1479-5876-11-9